Communicators

are winners!

More News

17.12.2025
Over 40% of Adults Struggle to Swallow Pills – BioNxt Targets a Global Adherence Problem with Rapid-Dissolving Thin-Film “Melt-in-Your-Mouth” Therapies
09.12.2025
BioNxt Advances "Melt in Your Mouth" Cladribine Formulation to Improve Treatment for MS Patients with Dysphagia
01.12.2025
BioNxt Signs Letter Agreement to Acquire 100% Interest in IP and to Codevelop a Sublingual Drug Formulation for Chemotherapy and Immunosuppressant Treatments
20.11.2025
BioNxt Secures Final Patent Grant from the Eurasian Patent Organization for Sublingual Cladribine Platform
04.11.2025
BioNxt Reports "Intention to Grant" Patent Notification from the European Patent Office for Its Oral Cladribine Sublingual Thin-Film
30.10.2025
BioNxt Reports "Readiness to Grant" Patent Notification from the Eurasian Patent Organization
21.10.2025
BioNxt Launches 15-day Sublingual Cladribine Dosing Optimization Study in Preparation for Human Bioequivalence Study
09.10.2025
BioNxt Completes “Fast-Track” US Track One Patent Filing for Sublingual Delivery of Cladribine for the Treatment of Multiple Sclerosis
02.10.2025
BioNxt Reports Update on Targeted Chemotherapy Drug Delivery Platform
29.09.2025
BioNxt Reports Sublingual Cladribine Multiple Sclerosis Drug Milestones including Large-Animal Study for Validation and Dosing Optimization